Serious hyperkalaemia after short use of low molecular weight heparin in a diabetic patient.
Rippin
J D
JD
Hado
H S H
HS
Green
Neil
N
Elhadd
T A
TA
D000208:Acute Disease; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D017985:Dalteparin / Q000008:administration & dosage / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000188:drug therapy; D008875:Middle Aged; D011137:Polystyrenes / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy; D013997:Time Factors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D011137:Polystyrenes; C003321:polystyrene sulfonic acid; D017985:Dalteparin